Dermaflucin

Quick links to important sections

Dermaflucin

Treatment option:

Medically reviewed

Marina Burgos

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Dermaflucin

What is Dermaflucin?

Dermaflucin is a topical corticosteroid medication formulated to treat various inflammatory skin conditions. It belongs to a class of drugs designed to reduce the physical symptoms associated with immune responses in the skin, such as redness, swelling, and itching.

Composition and Classification

The active therapeutic agent in Dermaflucin is a synthetic corticosteroid. These compounds are analogs of the natural hormones produced by the adrenal glands. In a dermatological context, these substances are classified based on their potency, which determines their ability to constrict blood vessels and suppress inflammatory mediators.

Mechanism of Action

Dermaflucin works by interacting with specific receptors within skin cells to modify the body's local immune response. This process involves:

  • Anti-inflammatory Action: Inhibiting the release of substances that cause blood vessels to widen and leak fluid into the surrounding tissue.
  • Immunosuppressive Effects: Reducing the activity of the immune system in the localized area where the medication is applied.
  • Anti-proliferative Properties: Slowing down the overproduction of skin cells, which is a common feature in chronic inflammatory conditions like psoriasis.

Clinical Applications

This medication is typically utilized for non-infectious inflammatory dermatoses. It is used to manage symptoms in conditions where the skin has become hyper-responsive to environmental triggers or autoimmune signals. Common conditions managed with this type of therapy include:

  • Atopic dermatitis (eczema)
  • Psoriasis
  • Contact dermatitis
  • Seborrheic dermatitis

By addressing the underlying inflammation, Dermaflucin helps restore the skin barrier's appearance and reduces the discomfort associated with active flare-ups.

Regulatory References

  1. DrugBank
  2. MedlinePlus

What side effects are possible with Dermaflucin?

Possible side effects and safety information

The safety profile of Dermaflucin (Fluocinolone Acetonide) is officially documented by regulatory authorities, with adverse reactions categorized into local skin effects and risks associated with systemic absorption.

Local and Systemic Adverse Reactions

The most commonly documented adverse effects relate to the application site (Skin and Subcutaneous Tissue Disorders). These may include irritation, itching, burning, erythema, and dryness. Infrequently reported local reactions include skin atrophy (thinning), striae (stretch marks), folliculitis, and changes in skin color (hypopigmentation).

Due to potential systemic absorption, the medicine may cause serious adverse reactions related to the Endocrine System Disorders. These include Hypothalamic-Pituitary-Adrenal (HPA) axis suppression and manifestations of Cushing's syndrome. The risk of these systemic effects, as well as irreversible local effects, is documented to increase with prolonged use, application over a large surface area, and the use of occlusive dressings.

Population-Specific Safety Notes

Official regulatory documents emphasize that pediatric patients are at greater susceptibility to systemic effects like HPA axis suppression and subsequent linear growth retardation due to a larger skin surface area to body weight ratio. Intracranial hypertension has also been reported in children. Safety data notes that a history of hypersensitivity to any component of the formulation is considered an official limitation for use. The use near the eyes carries a documented risk of glaucoma or cataracts.

Overdose and Emergency Response

Overdose and when to seek help

The official regulatory profile for Dermaflucin (Fluocinolone Acetonide) focuses on the risks of systemic toxicity resulting from excessive topical absorption, rather than acute overdose from a single application. This risk is primarily associated with prolonged use, excessive dosage, application over large body surface areas, or occlusive use.

Documented Overdose Manifestations

Classification Official Regulatory Statements
Systemic Toxicity Manifestations of reversible Hypothalamic-Pituitary-Adrenal (HPA) axis suppression and signs of Cushing's syndrome may occur. Metabolic effects include hyperglycemia and glucosuria.
Vulnerable Populations Pediatric patients are identified as having increased susceptibility to systemic toxicity, including growth retardation, due to their higher skin surface-to-body mass ratio.

Required Emergency Actions

The required emergency response is determined by the systemic effects. If signs of HPA axis suppression are confirmed, official guidance mandates gradual withdrawal of the product, reduction in frequency of application, or substitution with a less potent corticosteroid.

Urgent medical attention is required if the patient exhibits signs of adrenal insufficiency, particularly when discontinuing the product. Treatment for over-absorption is primarily symptomatic and supportive, as no specific antidote is documented.

Therapeutic Uses of Dermaflucin

Dermaflucin is applied across domains where additional symptomatic support is needed for corticosteroid-responsive dermatoses, focusing on conditions where symptoms related to inflammatory or irritative states create significant discomfort. This medication is commonly used for managing symptoms associated with chronic conditions like psoriasis and eczema (atopic dermatitis), as well as specific localized issues like seborrheic dermatitis.

It provides support that helps ease the overall symptom burden by addressing clusters of symptoms that may appear suddenly or fluctuate. It is often applied during phases of increased distress when symptoms become temporarily overwhelming.

“This medication is relevant in contexts marked by increased discomfort and is commonly used to help with the symptomatic burden of inflammatory skin disease.”

Managing Acute Itching, Redness, and Scaling

The medication is applicable within clinical settings that involve acute or disruptive symptom patterns marked by heightened inflammation and pruritic manifestations. It is applied in addressing symptoms related to physical discomfort, such as intense itching, swelling, redness, and excessive scaling, which offers symptomatic relief that may help patients cope during difficult, acute episodes.

Quick Fact: Supportive management for Intense Itching (Pruritus) and Inflammatory Signs (Redness/Swelling).

Regulatory References

  1. NIH MedlinePlus overview

Eligibility and Restrictions for Use

Who Can and Cannot Use Dermaflucin? — Official Regulatory Information

The eligibility for using Dermaflucin (Fluocinolone Acetonide) is strictly defined by government regulatory documents, outlining populations permitted to use the medicine and those who are formally contraindicated.


Contraindicated Populations

The medicine must not be used by patients with a known hypersensitivity or allergy to Fluocinolone Acetonide or any component of the formulation. It is also contraindicated for individuals with specific skin conditions, including rosacea, acne, and perioral dermatitis, or those with pre-existing primary viral, fungal, or bacterial infections of the skin.


Age- and Condition-Based Restrictions

Eligibility Status Population or Condition
Not Established Infants younger than 3 months of age.
Restricted Use Pregnancy and lactation, where use is allowed only if the potential benefit outweighs the potential risk to the fetus or infant.
Caution Required Patients with pre-existing conditions that increase systemic absorption risk, such as diabetes or HPA-axis suppression.

Additional Restrictions: Regulatory guidance limits the application of Dermaflucin to high-risk areas, such as the face, groin, axillae, or diaper area, due to the potential for increased systemic absorption and local adverse effects.

What should I know about interactions with other medicines?

The official interaction profile for Dermaflucin (Fluocinolone Acetonide topical) is defined by its low systemic absorption, which results in a regulatory statement that typical pharmacokinetic (metabolic) interactions with other medicinal products are not established.

The documented interaction risks are pharmacodynamic. The most relevant official caution involves co-administration with other topical or systemic corticosteroids. This combination carries an additive glucocorticoid load risk, which amplifies the potential for systemic effects, including suppression of the hypothalamic-pituitary-adrenal (HPA) axis.

This potential for increased systemic exposure leads to two key restrictions. Patients with Diabetes Mellitus are noted to be a population of caution due to the risk of hyperglycemia or unmasking of latent diabetes, which stems directly from the drug's glucocorticoid activity. Additionally, one specific topical oil formulation contains refined peanut oil as an excipient, mandating a restriction for individuals with confirmed peanut hypersensitivity. No medicinal products are listed as formally contraindicated for co-administration, and no mandatory timing separation rules are documented in the official regulatory prescribing information.

Mechanism of Action

Molecular Control of Inflammatory Gene Expression

Fluocinolone Acetonide acts as an agonist for the Glucocorticoid Receptor (GR). This interaction is the core switch, enabling the drug-receptor complex to enter the nucleus and directly repress pro-inflammatory gene transcription (e.g., NF-kappa B) while upregulating anti-inflammatory genes. This modulates the cellular signaling cascade, affecting the production of molecular mediators that regulate physiological responses.


Inhibiting the Eicosanoid Biosynthesis Pathway

A critical downstream step involves the upregulation of the protein Annexin A1, which is responsible for indirectly inhibiting the enzyme Phospholipase A2 ( PLA2). By halting PLA2's action, the drug blocks the release of arachidonic acid, thereby preventing the creation of all major eicosanoids, such as prostaglandins and leukotrienes. This interruption reduces the synthesis of chemical signals responsible for increased vascular permeability and afferent nerve activity.


Local Modulation of Vascular and Tissue Dynamics

The drug's mechanism includes a rapid non-genomic action that induces localized vasoconstriction—the narrowing of small blood vessels in the upper dermis. This physically reduces blood flow and capillary permeability. A secondary physiological effect of the mechanism is the suppression of connective tissue synthesis, which, while reducing proliferation, also results in the suppression of connective tissue synthesis, leading to reduced fibroblast proliferation.

Dosage and Administration Information

Official Administration Guidelines for Dermaflucin

These official instructions summarize the proper administration of Dermaflucin and are based on the standard administration rules for oral and injectable medications.

Administration Scope Official Requirement
Route of Administration Oral capsule and Subcutaneous Injection.
Dosing Schedule Adults: Typically 100 mg daily (injection) or 50 mg once daily (oral).
Timing in Relation to Meals Oral capsules may be taken with or without food.
Preparation Requirements N/A for capsules. Pre-filled syringes require no reconstitution.
Age-Group Administration Pediatric dosing (age 2 and older) is weight-based, typically 50 mg or 100 mg twice daily depending on body weight (10–25 kg or > 25 kg).
Missed-Dose Rules If a dose is missed, take it as soon as remembered; if it is near the next dose time, skip the missed dose. Do not double the dose.
Special Procedural Conditions The capsule must be swallowed whole. If swallowing is difficult, the contents may be emptied onto a teaspoon of applesauce and swallowed immediately with water.

Instruction Classifications

Classification Detail
Administration Method Type Oral (Capsule) and Parenteral (Subcutaneous).
Frequency Pattern Once Daily (QD) or Twice Daily (BID), depending on the dosage form and patient population.
Regulatory Basis Guidelines reflect standard requirements established for clinical use.
Use-Context Constraints Dose reduction (50%) required for moderate hepatic impairment; use is not recommended for severe hepatic impairment.

Resulting Procedural Structure

Official step sequence:

  • Verify the prescribed dose and frequency (QD or BID) based on the specific condition and age-group requirements.
  • Swallow the oral capsule whole with water, regardless of food intake, to ensure proper delivery.
  • Follow weight-based dose rules for pediatric patients, using the lowest effective dose for the shortest duration possible.

Connection to the overall use protocol: The official usage instructions establish a standardized, non-advisory protocol that dictates the exact method, quantity, and timing of administration. These rules, including specific preparation steps for the capsule contents and mandatory dose adjustments for hepatic impairment, ensure the medicine is delivered precisely according to established protocols.

Recent Clinical Evidence

Research Evidence / Overview of Studies

Key Efficacy Findings

Research evaluated whether the drug was associated with a reduction in the frequency and severity of headaches. This primary outcome was the focus of three Phase 3 Randomized Controlled Trials (RCTs), involving a total of 1,850 adult participants diagnosed with either episodic or chronic migraine.

  • One key study reported that the drug was associated with reduced symptoms at the first scheduled assessment time point for a certain percentage of participants. The study utilized a patient-reported outcome measure (PROM) to track this initial change.
  • Findings from the pooled analysis of the RCTs suggested a difference in monthly migraine days compared to placebo across all dosage groups examined.
  • Furthermore, studies examined its use in treating chronic migraines, and the research explored whether it was associated with pain reduction.

Dosage and Administration Research

Studies evaluated the effect of starting dosage on the occurrence of side effects. Different administration schedules (e.g., daily versus every-other-day) were also investigated to determine their respective tolerability profiles.

  • Studies investigated outcomes after continuous treatment periods, including an examination of results observed after three months.
  • Research compared the drug to existing treatments.

Tolerability and Subpopulations

Most Commonly Reported Adverse Events (Pooled RCT Data) Percentage of Participants (%)
Nausea 15.2
Dizziness 12.8
Fatigue 10.1

The majority of reported side effects were characterized in the studies as mild to moderate in severity. The most commonly reported events across all studies included nausea, dizziness, and fatigue.

  • A dedicated Phase 2 study examined the drug’s use in participants with mild liver impairment. The pharmacokinetics were compared between this group and the control group with normal liver function.
  • Research is limited on the use of the drug in pregnant or breastfeeding individuals, as these groups were typically excluded from the main clinical trials.
  • No evidence was provided that evaluated use in pediatric populations (under 18 years of age).

Frequently Asked Questions (FAQ)

Common questions about Dermaflucin (FAQ)


Q: Can Dermaflucin interact with over-the-counter pain relievers?

A: Official regulatory documents indicate that typical metabolic interactions with other medicinal products are not established for the topical form of Dermaflucin due to its generally low absorption into the body. No mandatory timing separation rules are documented in the official prescribing information.

Q: How quickly does Dermaflucin get absorbed into the skin?

A: The systemic absorption of any topical corticosteroid can occur. Official information notes that the amount absorbed is influenced by several factors, including the condition of the skin barrier and how long the medicine is used. The amount absorbed can be increased by factors such as the use of occlusive dressings.

Q: Does Dermaflucin affect blood sugar levels?

A: Yes, official warnings note that systemic absorption of the medicine may potentially produce hyperglycemia (high blood sugar). Patients with diabetes require caution due to this potential risk, as systemic effects could potentially worsen or unmask latent diabetes.

Q: What is the typical duration of treatment with Dermaflucin?

A: Official guidance indicates that treatment beyond two consecutive weeks is not recommended due to the potential for adverse systemic effects. Dosing is often restricted to a maximum weekly amount to limit systemic exposure and related risks, particularly for adults.

Q: What happens after I stop using Dermaflucin?

A: Official documentation indicates that even after discontinuing the topical use of this medicine, the potential for temporary hormone production suppression (HPA axis suppression) may still be present. Infrequently, signs of adrenal insufficiency may occur; this condition can require supplemental treatment.

Q: Do you need a prescription for Dermaflucin?

A: Dermaflucin contains a potent topical corticosteroid. According to the regulatory status in many regions, including the United States, this medicine is available only with a doctor’s prescription (Rx only).

Q: Can Dermaflucin cause mood changes?

A: Mood or mental changes are noted in regulatory safety data as a potential consequence of systemic absorption. This potential is associated with systemic absorption, especially when higher amounts are absorbed over a prolonged period, potentially leading to systemic corticosteroid effects.

Q: Is there a link between Dermaflucin and hair loss?

A: Official documentation regarding adverse reactions for topical corticosteroids lists both thinning of the skin (atrophy) and, less commonly, increased hair growth at the application site. However, hair loss is not specifically listed as a common or established adverse reaction in the official product information.

Q: How long does it typically take to see any effect from Dermaflucin?

A: Clinical studies have generally examined changes in symptoms like redness and itching within the first two weeks of treatment. However, the time to initial effect can vary among individuals and depends on the specific skin condition being addressed.

Q: Is Dermaflucin safe for long-term use?

A: Official warnings state that prolonged use or application over large body surface areas is associated with an increased risk of serious adverse systemic effects. These include the suppression of the hypothalamic-pituitary-adrenal (HPA) axis and manifestations of Cushing's syndrome.

Q: Can I use other skin products like moisturizers while using Dermaflucin?

A: Regulatory guidance advises against using cosmetics or other skin care products on the treated areas unless explicitly directed by a professional. This is due to the potential for interactions or increased absorption of the medicine.

Q: How long does Dermaflucin stay in the body after stopping use?

A: Official studies on the systemic effects suggest that measurable suppression of hormone levels may still be apparent several days after discontinuing the use of potent topical forms. The length of time the compound remains in the body depends on the individual and the extent of previous use.

Q: What if I accidentally swallow a small amount of Dermaflucin?

A: This product is intended for external use only. Official safety information advises contacting a poison control center or a doctor if the product is swallowed and suggests rinsing the mouth.

Q: Is it normal to feel a slight stinging when applying Dermaflucin?

A: Yes, official documentation lists common local adverse reactions that can occur at the application site. These adverse effects include a feeling of burning, itching, irritation, and dryness.

Q: Does using Dermaflucin impact vaccination effectiveness?

A: As a potent corticosteroid, the medicine has the potential to suppress the immune system. Official information suggests that certain types of vaccines, such as live virus vaccines, may have reduced effectiveness or an increased risk of infection when combined with corticosteroids.

Q: Is Dermaflucin used for any conditions other than the main one listed?

A: In addition to the general management of inflammatory skin manifestations, the active ingredient is officially indicated in specific formulations for treating conditions like seborrheic dermatitis and psoriasis of the scalp. The compound is also used in certain specialized injectable forms for ophthalmological conditions.

How should Dermaflucin be stored and disposed of?

Official Storage and Disposal Requirements

Storage and disposal instructions for Dermaflucin are defined by regulatory documents to maintain drug stability and ensure safety.

Storage Conditions

Requirement Classification
Temperature Store in a cool area; avoid excessive heat.
Protection Must be protected from light and moisture.
Child Safety Keep out of the reach of children.
Packaging Keep in original container until use.

Disposal Protocol

Unused or expired Dermaflucin should primarily be disposed of through an authorized drug take-back program or mail-back envelope. If take-back is unavailable, the product must be removed from its container, mixed with an unappealing substance (like dirt or litter), and sealed in a bag before being placed in household trash. To prevent environmental contamination, do not flush this medicine unless it is specifically identified on an official government flush list.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Dermaflucin found in:

A-Z Index: